Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00316264




Registration number
NCT00316264
Ethics application status
Date submitted
18/04/2006
Date registered
20/04/2006
Date last updated
11/12/2012

Titles & IDs
Public title
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
Scientific title
A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season
Secondary ID [1] 0 0
MI-CP127
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Chronic Lung Disease and <= 24 Months of Age or 0 0
Premature With Gestational Age <=35 Weeks and <=6 Months of Age 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Motavizumab, palivizumab
Treatment: Other - Palivizumab, motavizumab
Treatment: Other - Motavizumab

Experimental: Motavizumab followed by Palivizumab - 2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)

Experimental: Palivizumab followed by motavizumab - 2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)

Experimental: Motavizumab control - 5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)


Treatment: Other: Motavizumab, palivizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.

Treatment: Other: Palivizumab, motavizumab
Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.

Treatment: Other: Motavizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects Reporting Serious Adverse Events (SAEs)
Timepoint [1] 0 0
Day 0 - Day 150
Primary outcome [2] 0 0
Number of Subjects Reporting Adverse Events (AEs)
Timepoint [2] 0 0
Day 0 - Day 150
Primary outcome [3] 0 0
Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.
Timepoint [3] 0 0
Day 0 - Day 150
Secondary outcome [1] 0 0
The Serum Concentrations of Motavizumab at Day 0
Timepoint [1] 0 0
Day 0
Secondary outcome [2] 0 0
The Trough Serum Concentrations of Motavizumab at Day 60
Timepoint [2] 0 0
Day 60
Secondary outcome [3] 0 0
The Trough Serum Concentrations of Motavizumab at Day 150
Timepoint [3] 0 0
Day 150
Secondary outcome [4] 0 0
The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose
Timepoint [4] 0 0
120-150 days post final dose
Secondary outcome [5] 0 0
The Serum Concentrations of Palivizumab at Day 0
Timepoint [5] 0 0
Day 0
Secondary outcome [6] 0 0
The Trough Serum Concentrations of Palivizumab at Day 60
Timepoint [6] 0 0
Day 60
Secondary outcome [7] 0 0
The Trough Serum Concentrations of Palivizumab at Day 150
Timepoint [7] 0 0
Day 150
Secondary outcome [8] 0 0
The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose
Timepoint [8] 0 0
120-150 days post final dose
Secondary outcome [9] 0 0
The Immunogenicity of Motavizumab at Day 0
Timepoint [9] 0 0
Day 0
Secondary outcome [10] 0 0
The Immunogenicity of Motavizumab at Day 60
Timepoint [10] 0 0
Day 60
Secondary outcome [11] 0 0
The Immunogenicity of Motavizumab at Day 150
Timepoint [11] 0 0
Day 150
Secondary outcome [12] 0 0
The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose
Timepoint [12] 0 0
120 - 150 days post final dose
Secondary outcome [13] 0 0
The Immunogenicity of Motavizumab at Any Time
Timepoint [13] 0 0
At any time
Secondary outcome [14] 0 0
The Immunogenicity of Palivizumab at Day 0
Timepoint [14] 0 0
Day 0
Secondary outcome [15] 0 0
The Immunogenicity of Palivizumab at Day 60
Timepoint [15] 0 0
Day 60
Secondary outcome [16] 0 0
The Immunogenicity of Palivizumab at Day 150
Timepoint [16] 0 0
Day 150
Secondary outcome [17] 0 0
The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose
Timepoint [17] 0 0
120 - 150 days post final pose
Secondary outcome [18] 0 0
The Immunogenicity of Palivizumab at Any Time
Timepoint [18] 0 0
At any time

Eligibility
Key inclusion criteria
* The child must have been born at less than or equal to 35 weeks gestation and be less than or equal to 6 months of age at the time of entry into the study (child must be entered on or before his/her 6-month birthday); or the child must be less than or equal to 24 months of age at the time of entry into the study (child must be entered on or before his/her 24-month birthday) and diagnosed with chronic lung disease (CLD) of prematurity with stable or decreasing doses of diuretics, steroids, or bronchodilators, or treatment with supplemental oxygen, within the previous 6 months.
* The child must be in general good health at the time of study entry.
* The child's parent(s)/legal guardian must provide written informed consent.
* The child must be able to complete the follow-up visits through 120-150 days from last injection of study drug.
* Parent(s)/legal guardian of patient must have available telephone access.
Minimum age
No limit
Maximum age
24 Months
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Hospitalized at the time of study entry (unless discharge is expected within 10 days after entry into the study)
* Receiving chronic oxygen therapy or mechanical ventilation at the time of study entry (including continuous positive airway pressure [CPAP])
* Congenital heart disease (CHD) (children with medically or surgically corrected [closed] patent ductus arteriosus and no other CHD may be enrolled)
* Evidence of infection with hepatitis A, B, or C virus
* Known renal impairment, hepatic dysfunction, chronic seizure disorder, or immunodeficiency or HIV infection (a child of a mother with known HIV infection must be proven to be uninfected at the time of enrollment)
* Suspected serious allergic or immune-mediated events with prior receipt of palivizumab
* Acute illness or progressive clinical disorder
* Active infection, including acute RSV infection, at the time of enrollment
* Previous reaction to intravenous immunoglobulin (IGIV), blood products, or other foreign proteins
* Received within the past 120 days or currently receiving immunoglobulin products (such as RSV-IGIV [RespiGam], IVIG, or palivizumab) or any investigational agents
* Previous participation in a clinical trial of motavizumab
* Currently participating in any investigational study

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2007
Sample size
Target
Accrual to date
Final
260
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Department of Paediatrics and Child Health, The Canberra Hospital - Garran
Recruitment hospital [2] 0 0
Neonatalogy John Hunter Hospital - New Lambton Heights
Recruitment hospital [3] 0 0
Caboolture Clinical Research - Caboolture
Recruitment hospital [4] 0 0
University of Queensland, Royal Children's Hospital - Herston
Recruitment hospital [5] 0 0
Peninsula Clinical Research Centre - Kippa-Ring
Recruitment hospital [6] 0 0
Women's and Children's Hospital - North Adelaide
Recruitment hospital [7] 0 0
Respiratory Medicine Department, Royal Children's Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
4510 - Caboolture
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
4021 - Kippa-Ring
Recruitment postcode(s) [6] 0 0
5006 - North Adelaide
Recruitment postcode(s) [7] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
Chile
State/province [1] 0 0
Santiago
Country [2] 0 0
New Zealand
State/province [2] 0 0
Auckland
Country [3] 0 0
New Zealand
State/province [3] 0 0
Christchurch
Country [4] 0 0
New Zealand
State/province [4] 0 0
Dunedin
Country [5] 0 0
New Zealand
State/province [5] 0 0
Hamilton
Country [6] 0 0
New Zealand
State/province [6] 0 0
Palmerston North

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
MedImmune LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pamela Griffin, M.D.
Address 0 0
MedImmune LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Fernandez P, Trenholme A, Abarca K, Griffin MP, Hu... [More Details]

Results are available at https://clinicaltrials.gov/study/NCT00316264